A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 microg qd delivered by 2 different dry powder inhalers (Aerolizer and Almirall Inhaler), of the Fixed Dose Combination formoterol 12 microg + Aclidinium bromide 200 microg qd delivered by Almirall Inhaler, and of formoterol 12 microg bid delivered by Aerolizer, in moderate to severe Chronic Obstructive Pulmonary Disease Patients.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Aclidinium bromide/formoterol; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 25 Jul 2011 New trial record